Europe rues SVB loss as a cornerstone life science supporter
With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?
Silicon Valley Bank: biopharma’s latest crisis
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Flotations versus blank cheques
Neither route to the stock market covered itself in glory in the recent bull market. But how do returns really stack up?
The ink dries on the blank cheque craze
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?